Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-15
2008-01-15
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252020, C514S252110, C514S252140, C514S253010, C514S255030, C544S209000, C544S212000, C544S238000, C544S295000, C544S357000, C544S360000, C544S391000
Reexamination Certificate
active
10911359
ABSTRACT:
The invention relates to compounds of formulawherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
REFERENCES:
patent: 5081112 (1992-01-01), Tsutsumi et al.
patent: 6916804 (2005-07-01), Castelhano et al.
patent: 0 171 636 (1985-02-01), None
patent: WO 02/22612 (2002-03-01), None
Lewis D.A. & Lieberman J.A., Neuron. vol. 28, pp. 325-334 (2000).
Vandenberg R. J. & Aubrey K. R., Exp. Opin. Ther. Targets vol. 5(4) pp. 507-518 (2001).
Nakazato A. & Okuyama S., Exp. Opin. Ther. Patents vol. 10(1) pp. 75-98 (2000).
Sharma T., Br. J. Psychiatry, vol. 174 (Suppl. 28) pp. 44-51 (1999).
Javitt D. C. et al., Biol. Psychiatry, vol. 45 pp. 668-679 (1999).
Mohn A. R., Cell vol. 98 pp. 427-436 (1999).
Bliss, T. V. & Collingridge G. L., Nature, vol. 361 pp. 31-39 (1993).
Tang J. P. et al., Nature, vol. 401, pp. 63-69 (1999).
Gainetdinov R. R. et al., Trends in Pharm. Sci. vol. 23(8) pp. 367-373 (2002).
Lopez-Corcuera B, et al., Mol. Mem. Biol. vol. 18 pp. 13-20 (2001).
Bergeron R. et al., Proc. Natl. Acad. Sci. USA vol. 95, pp. 15730-15734 (1998).
Chen et al., J. Neurophysiol. vol. 89(2) pp. 691-703 (2003).
Armer R. E. & Miller D. J., Exp. Opin. Ther. Patents vol. 11(4) pp. 563-572 (2001).
Pralong E. et al., Prog. Neurobiol. vol. 67, pp. 173-202 (2002).
Carlsson M. L., J. Neural Trans. vol. 105, pp. 525-535 (1998).
Chem. Abstract XP-002299148, Chemcats No. 2004:3653471 (2004).
Caulfield W. L. et al., Journal of Med. Chem. vol. 44(17) pp. 2679-2682, 2001.
Chem. Abstract XP-002299149, Chemcats No. 2004:2179871 (2004).
Jolidon Synese
Narquizian Robert
Nettekoven Matthias Heinrich
Norcross Roger David
Pinard Emmanuel
Bernhardt Emily
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
Benzoyl-piperazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzoyl-piperazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzoyl-piperazine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3947865